Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?

× No keyword cloud information.

26 in total

1. Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine.

Authors: Nicholas R Latimer; Keith R Abrams; Mayur M Amonkar; Ceilidh Stapelkamp; R Suzanne Swann
Journal: Oncologist Date: 2015-06-03

Review 2. Endpoints and cutpoints in head and neck oncology trials: methodical background, challenges, current practice and perspectives.

Authors: Marcus Hezel; Kathrin von Usslar; Thiemo Kurzweg; Balazs B Lörincz; Rainald Knecht
Journal: Eur Arch Otorhinolaryngol Date: 2015-01-09 Impact factor: 2.503

3. Trends in endpoint selection in clinical trials of advanced breast cancer.

Authors: Seung Yeon Song; Heenam Seo; Gyungjin Kim; Ah Rong Kim; Eun Young Kim
Journal: J Cancer Res Clin Oncol Date: 2016-09-01 Impact factor: 4.553

4. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.

Authors: Karim Fizazi; Robert Jones; Stephane Oudard; Eleni Efstathiou; Fred Saad; Ronald de Wit; Johann De Bono; Felipe Melo Cruz; George Fountzilas; Albertas Ulys; Flavio Carcano; Neeraj Agarwal; David Agus; Joaquim Bellmunt; Daniel P Petrylak; Shih-Yuan Lee; Iain J Webb; Bindu Tejura; Niels Borgstein; Robert Dreicer
Journal: J Clin Oncol Date: 2015-01-26 Impact factor: 44.544

5. Survival of de novo stage IV breast cancer patients over three decades.

Authors: Dieter Hölzel; Renate Eckel; Ingo Bauerfeind; Bernd Baier; Thomas Beck; Michael Braun; Johannes Ettl; Ulrich Hamann; Nadia Harbeck; Marion Kiechle; Sven Mahner; Christian Schindlbeck; Johann de Waal; Jutta Engel
Journal: J Cancer Res Clin Oncol Date: 2016-11-16 Impact factor: 4.553

6. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

Authors: Carla Casulo; Michelle Byrtek; Keith L Dawson; Xiaolei Zhou; Charles M Farber; Christopher R Flowers; John D Hainsworth; Matthew J Maurer; James R Cerhan; Brian K Link; Andrew D Zelenetz; Jonathan W Friedberg
Journal: J Clin Oncol Date: 2015-06-29 Impact factor: 44.544

Review 7. Validation and clinical utility of prostate cancer biomarkers.

Authors: Howard I Scher; Michael J Morris; Steven Larson; Glenn Heller
Journal: Nat Rev Clin Oncol Date: 2013-03-05 Impact factor: 66.675

Review 8. Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available.

Authors: Catherine Beauchemin; Marie-Ève Lapierre; Nathalie Letarte; Louise Yelle; Jean Lachaine
Journal: Pharmacoeconomics Date: 2016-09 Impact factor: 4.981

9. Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.

Authors: T E Delea; A Khuu; D Y C Heng; T Haas; D Soulières
Journal: Br J Cancer Date: 2012-08-30 Impact factor: 7.640

10. Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy.

Authors: Eugene R Ahn; Emilie Wang; Stefan Glück
Journal: Breast Cancer (Auckl) Date: 2012-11-19